Bausch + Lomb's shares dropped significantly during trading on Friday following the company's announcement of a voluntary recall of certain intraocular lenses due to safety issues. The recall includes the enVista Aspire, enVista Envy, and some enVista monofocal lenses in the U.S. The decision was made due to an increased number of reported cases of toxic anterior segment syndrome (TASS) associated with these lenses. This move was a precautionary measure as the company investigates the causes of the complications.

Intraocular lenses are used in cataract surgery to replace the natural lens and enhance vision. TASS, an inflammatory reaction within the eye, can occur after cataract surgery within 12 to 48 hours. Bausch + Lomb expressed that TASS is a known potential complication of cataract surgery.

Bausch + Lomb's stock experienced a nearly 5% decline in Friday's intraday trading session and has seen a decrease of about 17% in its value over the past year.